Search

Valve-in-valve transcatheter aortic valve replacement (ViV TAVR) is an appealing alternative to surgical intervention on failed aortic prosthesis with comparable safety and efficacy. ViV TAVR has proven to be a technical challenge in stentless bioprosthetic aortic valves like free style aortic valve prosthesis. In this case series of two patients we report the utility of transesophageal echocardiogram guidance to help visualize surgical annulus and TAVR deployment.

Veno-arterial membrane oxygenation (VA-ECMO) can be used as a rescue therapy for patients in refractory cardiogenic shock. While there is experience as a bridge-to-transplant and bridge-to-ventricular assist device in the heart failure population, there are not reports of its use as a bridge to definitive valvular intervention. Here we present a case of VA-ECMO as a bridge to transcatheter mitral valve-in-valve (TMVIV) with a Sapien aortic prosthesis (Edwards Life Sciences, Irvine, CA).

Purpose . The purpose of this work was to study the midterm results after the implantation of a frame-mounted xenopericardial bioprosthesis into the aortic position with the easy-change system. Material and Methods . A total of 166 patients with mean age of 69.5 years underwent aortic valve replacement by bioprosthesis with the easy-change system at Cardiology Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences between October, 2016 and October, 2020. Preoperative aortic valve peak pressure gradient was 79.6 mmHg; the mean gradient was elevated up to 46.3 mmHg. Echocardiography studies of aortic prosthesis and the left ventricle (LV) were performed in all patients by Vivid 7, GE, and IE 33 systems (Philips) preoperatively, before the discharge (day 14 after surgery on average), and 6–12 months after surgery. Results . The control echocardiography studies, performed 6–12 months after surgery, showed that the hemodynamic characteristics of MedEng-BIO aortal bioprostheses were satisfactory. No statistically significant changes in the LV function were detected. The effective orifice areas of MedEng-BIO valves were 0.87 cm 2 for the valve size 21, 1.1 cm 2 for size 23, and 1.47 cm 2 for size 25 mm. The peak pressure gradient decreased by 57.8% and the mean gradient decreased by 51.9% two years after surgery. Conclusion . Obtained data suggest that the implantation of MedEng-BIO aortal xenopericardial bioprosthesis into the aortic position lead to adequate correction of hemodynamic parameters.

Clinical data A 65-year-old female patient was hospitalized, initially due to an episode of melena. Anticoagulation was suspended, and upper gastrointestinal endoscopy was performed, without detecting bleeding. In 2005, she had late post-operative history of mechanical aortic prosthesis and Bentall and de Bono surgery due to Stanford A aortic dissection; she was a former tobacco user, with obesity and chronic atrial fibrillation under regular use of warfarin. The following day, she had an acute myocardial infarction with ST-segment elevation in [...]

We present the case of a 73-year-old male patient undergoing a modified Bentall-DeBono procedure in 2015 due to aortic stenosis and aortic aneurism involving the root. A bioprosthetic stented conduit made with a stented Edwards Perimount 21-mm bioprosthesis and a Vascutek Valsalva 28-mm Dacron graft was implanted along with a mitral annuloplasty. Five years later, due to early degeneration of the bioprosthesis and a progression of the mitral disease, he underwent a second surgical procedure where a Medtronic Mosaic 27-mm valve prosthesis was implanted in mitral position and a sutureless Livanova Perceval 23-mm valve in aortic position. Because of the difficulty in removing the previously implanted aortic prosthesis, the Perceval valve was inserted inside the frame of the PeriMount as an open "valve-in-valve" procedure. In October 2020, the patient underwent a ViV TAVI with a 23-mm Edwards Sapien 3 (Edwards Lifescience). After induction of general anesthesia and heparin administration, the procedure was performed via right femoral artery approach with preimplantation of two Proglides. After transfemoral insertion of a 14-French sheath, the aortic valve was crossed with a 0.035-in. straight guide-wire, taking care to avoid crossing the crowns of Perceval frame. After exchange of the standard wire with an extra-stiff 0.035-in. Safari wire, the Sapien-3 valve was advanced across the two previously implanted surgical valves and deployed at the level of the Perceval ring. After bioprosthesis deployment, peak-to-peak left ventricular aortic gradient was reduced from 51 to 16 mmHg.

Endovascular prostheses are used to treat life-threatening conditions such as ruptured aortic aneurysms. Prosthetic infection cause significant morbidity and mortality, posing important diagnostic and therapeutic challenges. It is particularly difficult to diagnose and, in the era of multidrug resistance (MDR), these type of infections may become even more difficult to treat. Herein, we reported a case of a secondary prosthetic endovascular infection following repeated bacteremia episodes from a urinary source. This case illustrates an MDR Pseudomonas aeruginosa aortic infection that was difficult to diagnose with no oral antibiotic treatment options.

Thoracic aortic aneurysm is one of the most serious pathologies of cardiovascular surgery. Occurrence of an aneurysm in the proximal or distal part of the aortic arch is a recognized complication of uncorrected aortic coarctation and is associated with a significant risk of aortic rupture. The article presents a case of surgical treatment of a 36-year-old woman with untreated hypoplasia of the arch and coarctation of the aorta. Our experience shows that the operation of anatomical ascendo-descendoaortic prosthetics is a useful and safe method of surgery in patients with aortic arch aneurysms at high risk of endovascular or hybrid types of interventions

Background The ease of implantation of the rapid deployment (RD) and sutureless valves has contributed to the adoption of anterior right thoracotomy (ART) approach for aortic valve replacement (AVR). Aim of the study This study evaluates the safety and haemodynamic performance of minimally invasive AVR through ART using the RD valves. Methods This is a retrospective, single-center review of a total of 50 consecutive patients who received RD-AVR through ART. Results The median age of patients was 75 years (interquartile range [IQR]: 69-80), and median Euroscore II was 5.1 (IQR: 2.4-7.5). ART RD-AVR was successfully performed in all cases with no conversion to sternotomy, paravalvular leaks or need for valve explantation. The mean size of the implanted valve was 23.2 ± 2.3 mm. In-hospital mortality was 2%. The mean and maximum pressure gradients across the aortic prosthesis were 10 mm Hg (IQR: 9-12) and 19 mm Hg (IQR: 16-23). Conclusions Rapid deployment aortic valve replacement can be safely performed through anterior right thoracotomy wit excellent haemodynamic performance and low postoperative complications rate.

A comprehensive understanding of normal prosthetic valve anatomy and function is essential to identify and evaluate pathologic states. Three dimensional echocardiography (3DE) and in particular 3D transesophageal echocardiography (3DTEE) provides exceptional enface atrial and ventricular views of mitral prostheses from a single acoustic window. By providing a panoramic view of mitral valve prostheses and surrounding bed, the sewing ring of surgical prostheses can be readily imaged, and prosthesis morphology including subtle findings that cannot be seen on two-dimensional echocardiography (2DE) can be better appreciated. Moreover, mechanical prosthesis occluder mechanism including spatial orientation of the occluder leaflets, and normal leaflet excursion can be ascertained. The added depth provided by 3D imaging allows visualization of mechanical aortic prosthesis occluder motion when not seen on 2D imaging, and a better appreciation of aortic and mitral bioprostheses cusp morphology. For patients who undergo, mitral valve repair, the annuloplasty band or ring can also be readily appreciated in the 3D space

Aim. To compare the outcomes of aortic valve replacement using the xenogenic aortic prosthesis Hancock II and the novel Russian xenogenic pericardial prosthesis MEDINGE-BIO.Material and methods. The study included patients operated on for aortic stenosis in the cardiac surgery department № 1 of the Cardiology Research Institute (Tomsk National Research Medical Center). All patients were divided into two groups. The first group included 54 patients with Hancock II prostheses, the second — 91 patients with MEDINGE-BIO prostheses. Hemodynamic characteristics of heart valves were assessed by echocardiography before surgery and before discharge (on average 10 days after surgery).Results. When comparing hemodynamic parameters before and after surgery, significant differences between the groups were not obtained. The average pressure gradient after surgery using Hancock II and MEDINGE-BIO prosthesis was 21,6±7,9 and 17,9±5,6 mm Hg, respectively (p=0,05).Conclusion. The comparative analysis showed that the novel biological prosthesis MEDINGE-BIO has comparable hemodynamic characteristics with the well-known aortic prosthesis Hancock II.

OBJECTIVES The Edwards Intuity valve is a rapid deployment aortic prosthesis that favours less invasive approaches. However, evidence about the clinical behaviour of their smaller sizes is scarce. Herein, we studied haemodynamic behaviours and clinical outcomes of small Intuity prostheses (19–21 mm) in comparison to larger Intuity prostheses (>21 mm). METHODS This is an observational study including patients implanted with an Edwards Intuity rapid deployment aortic prosthesis. Patients with prosthesis sizes 19–21 and >21 mm were included. Baseline and perioperative variables, as well as adverse events during the follow-up were recorded and compared between groups. RESULTS A total of 122 patients (37% female, mean age 75 ± 4.5 years) were included, of whom 54 (45%) were implanted with a small prosthesis and 68 (55%) with a prosthesis >21 mm. There were no significant differences between patients with small Intuity prostheses and patients with larger prostheses regarding in-hospital mortality (2% vs 4%, P = 0.43) or mortality during the follow-up (3.41 vs 2.45 per 100 patients-years; P = 0.58). Survival in the small Intuity valve group was 95% at 1 year and 83% at 6 years, whereas in the larger Intuity valve group was 96% at 1 year and 78% at 6 years. The presence of a small prosthesis did not influence mid-term survival (log-rank P-value = 0.62). CONCLUSIONS This study showed good clinical performance of Intuity aortic prostheses with appropriate mid-term survival in patients with the small aortic annulus. Thus, the Edwards Intuity rapid deployment aortic prosthesis may be considered as a potential option in patients with the small aortic annulus.

Valve-in-valve TAVR procedure stalled due to challenging aortic to prosthesis angle not allowing the advancement of the Evolut R into the failing 25 mm Magna prosthesis. Efforts to better align the TAVR device with the valve prosthesis by using conventional methods failed. Eventually, a buddy wire allowed advancement and successful deployment of the Evolut R 26 mm within the stenosed surgical valve. The role and methodology of buddy wire use in TAVR, valve-in-valve procedures (first report) and structural heart procedures is reviewed.

Background In our institution, we developed a modification of the standard implantation technique of the Perceval sutureless aortic prosthesis (LivaNova, London, United Kingdom) that involves the usage of snuggers for the guiding sutures during valve deployment. The technique has been described elsewhere. In this article, we present the results of our initial case series comprising 128 consecutive patients. Methods From September 2016 to June 2018, 128 patients received a sutureless Perceval prosthesis (mean age 72.2 ± 8.5 years, 66 males). The data of the patients were prospectively collected in our general database and retrospectively analyzed using the SPSS software version 25 (IBM SPSS Inc., Chicago, Illinois, United States). Primary end points were primary implantation success and 30-day mortality. All patients underwent transthoracic echocardiography on discharge. Results Our cohort consisted of real-world scenario patients with infective endocarditis, bicuspid aortic valves and one patient with left ventricular assist device. However, we had 100% primary implantation success with no need for valve explantation or paravalvular leaks. All-cause 30-day mortality was 2.3% (3 patients) with no cardiac deaths. Two patients (1.6%) had a permanent neurological deficit, three patients (2.3%) had new-onset renal dialysis, and four patients (3.1%) needed a permanent pacemaker postoperatively. Conclusion To our knowledge, this is the first case series to report on a modified implantation technique of the Perceval prosthesis. The Perceval valve prosthesis produces excellent outcome in most pathologies, so that current contraindications should be revised.

OBJECTIVES The goal of this study was to assess the performance and incidence of the deterioration of the Labcor Dokimos bioprosthetic aortic valve. METHODS We performed a retrospective medical chart review of 116 patients who underwent surgical aortic valve replacement with the Labcor Dokimos aortic valve between 2010 and 2018. Abstracted data included patient demographic and echocardiographic data. Patients were divided into 2 groups: patients with structural valve deterioration (SVD) and patients without SVD. RESULTS Among the patients with complete follow-up (n = 95), 10 patients were excluded because they died within a year; 85 patients were included in the final analysis. Of the 85 patients, 32 (38%) developed SVD; 22 (26%) had severe SVD, 15 (18%) of whom underwent reintervention. The most common aetiology of SVD was severe central aortic regurgitation, which was detected in 91% of the patients who had severe SVD. The average time from operation to severe SVD was 4.7 years with a minimum of 1.5 years and a maximum of 7.9 years. CONCLUSIONS Bioprosthetic aortic valve deterioration due to severe aortic regurgitation is common and occurs early with the Labcor Dokimos valve. This occurrence needs to be furthered investigated in larger registries.

Large studies demonstrated that moderate or severe patient-prosthesis mismatch (PPM) occurs in 44.2% to 65% of patients undergoing aortic valve replacement. If there is general agreement that patients with PPM have worse outcome than patients without, it is difficult to understand how to prevent this dangerous complication. The formula used to calculate the effective orifice area (EOA) of an implanted aortic prosthesis has many weak points that produce inconsistent results using the same prosthetic valve (type and size). The observed EOA (3 to 6 months postoperatively) of a #23 biological prosthesis can range from 0.9 to 3.5 cm², making PPM prevention impossible using projected EOA, where only the mean value is reported (1.83 cm² for the same #23 biological prosthesis). An EACTS-STS-AATS Valve Labelling Task Force has been established to suggest the manufacturers to present essential information on valvular prosthesis characteristics in standardized Valve Charts. For valves used in the aortic position, Valve Charts should include a standardized PPM chart to assess the probability of PPM after implantation. This will not solve completely the conundrum of prevention, but most likely it will be a step ahead.

Implantation of hybrid prostheses using the frozen elephant trunk technique has become a standard procedure for aortic arch and proximal descending aorta pathologies. New devices have been introduced to reduce surgical complexity by enabling the frozen elephant trunk technique to be performed in proximal segments of the aorta. This facilitates a minimally invasive approach and provides a safe and durable aortic arch repair. We herein report on the first human experience with the new trifurcated frozen elephant trunk aortic prosthesis, E-vita OPEN NEO (CryoLife/JOTEC GmbH, Hechingen, Germany), using a minimally invasive technique.

Available aortic prosthesis replacement options are challenged to achieve low perioperative morbidity, low pressure gradients, and prolonged durability. Trileaflet aortic valve reconstruction using autologous pericardium offers an alternative treatment option with excellent postoperative gradients, large effective orifice areas, and the avoidance of long-term anticoagulation. The modified Bentall procedure with either tissue xenograft valved conduit or mechanical valved conduit is considered the gold standard for patients with aortic root pathology requiring surgical replacement. We report a novel adaptation of the modified Bentall procedure with a self-fabricated valved conduit with trileaflet aortic valve neocuspidization using autologous pericardium. Currently available aortic prosthesis replacement options are challenged to achieve low perioperative morbidity, low pressure gradients, and prolonged durability. Trileaflet aortic valve reconstruction using autologous pericardium with the AVNeoTM system offers an alternative treatment option with excellent postoperative gradients, large effective orifice areas, and the avoidance of long-term anticoagulation1. Professor Ozaki reported excellent durability with over 95% of patients free from reoperation at 10-years1. The modified Bentall procedure with prosthesis valved conduit is considered the gold standard for patients with aortic root pathology requiring surgical replacement2. We report a novel adaptation of the modified Bentall procedure with a self-fabricated valved conduit with trileaflet aortic valve neocuspidization using autologous pericardium with the AVNeoTM system. Since the AVNeoTM template is a U.S. Food and Drug Administration approved device for treatment of aortic valve diseases1, institutional review board approval for this procedure was not necessary.

Background: Although aortic valve replacement (AVR) when successfully performed boasts low mortality rates in selected patients, prosthesis-patient mismatch (PPM) can be found in the majority of these individuals. Limited research is available supporting the benefit of two-dimensional speckle tracking echocardiography (2D-STE) in patients with severe PPM. This study sought to assess myocardial strain using 2D-STE to determine the relationship between subclinical left ventricular (LV) dysfunction and aortic PPM in patients undergoing AVR with preserved LV ejection fraction. Material and methods: We retrospectively examined all consecutive patients with isolated AVR who presented to our center from 2005 to 2018. The data of 1086 patients were analyzed. Severe PPM was defined as an indexed effective orifice area of 0.65 cm2/m2 or less. As a result of the detailed assessment, 54 patients meeting the eligibility criteria were included in the study. Baseline data were collected and compared between the two groups of patients with severe PPM (n = 27) and those with normofunctional aortic prosthesis valve as a control group (n = 27). All patients underwent baseline echocardiography. Global longitudinal strain (GLS) and global circumferential strain (GCS) were evaluated by 2D-STE. Results: When compared with controls, patients with severe PPM had significantly decreased GLS (18.6 ± 2.9 vs. 21.4 ± 2.1; p < 0.01) and GCS (17.2 ± 3.6 vs. 21.7 ± 2.1; p < 0.01) values. Conclusion: In addition to standard clinical and echocardiographic parameters, GLS and GCS suggest subclinical dysfunction and have incremental value in patients with severe PPM. WOS:000626782100001 33687479 Q4

The interposition of viable tissue between an aortic graft prosthesis and the posterior wall of the duodenum has long been recognized as an important technique to limit the incidence of graft-enteric erosions and fistulae. In patients with aortoiliac occlusive disease, the periaortic tissue is approximated over the aortic prosthesis to insulate the graft from the adjacent bowel.

BACKGROUND Early structural valve deterioration (SVD) frequently occurs in Mitroflow aortic bioprosthesis, especially for small sizes (19-mm and 21-mm), and it is associated with reduced overall survival. Treatment by percutaneous valve-in-valve (ViV) implantation is considered a challenging procedure. This is mainly due to an elevated risk of coronary ostia obstruction and high residual post-procedural mean gradients (mG), particularly when severe pre-existing patient-prosthesis mismatch (PPM) is present. PURPOSE Aim of our study was to assess the feasibility of transfemoral ViV in small Mitroflow aortic valves using supra-annular self-expanding valves, named CoreValve and Evolut R and Acurate neo and report the midterm clinical results by comparing serum natriuretic peptide type B levels (BNP) before the procedure and at a mean follow-up of 2 years. METHODS This is an observational study including 11 patients with stenotic-type SVD of small Mitroflow aortic valves, considered at high/prohibitive risk for surgical reoperation, who underwent ViV implantation between July 2012 and March 2018. We performed echocardiographic assessment of valve hemodynamics (according to VARC-2 definitions) before and after the procedure and during the follow-up. We used the BNP ratio (the ratio between measured serum BNP/NT-proBNP level and maximal normal level) to compare BNP results before the procedure and at follow-up. All-cause mortality during the hospitalization and follow-up was also reported. RESULTS The Mitroflow size was 19-mm in 4 patients and 21-mm in 7 patients. Pre-existing severe PPM was present in 4 patients and moderate PPM in 7. CoreValve 26 was implanted in 2 patients, EvolutR 23 in 5 and Acurate neo S in 4 patients. We reported no coronary obstruction, deaths or other major events during the hospitalization. At a mean follow-up of 2 years one patient died. The baseline aortic mG of 56 ± 19 mmHg has significantly reduced after the procedure to 16,6 ± 8 mmHg (p 3. Patients with mPG ≥20 mmHg did not show differences in terms of mortality and reduction of serum BNP levels. CONCLUSIONS In our experience the ViV procedure on small degenerated aortic Mitroflow bioprosthesis appears to be technically feasible and provides good midterm clinical results with a net reduction in serum BNP levels, although an increase in mG was observed. Even though a post-procedural mG ≥20 mmHg is considered indicative of suboptimal aortic valve hemodynamics (according to VARC-2 criteria), its correlation with worse outcomes remains unclear and deserves further investigations.

Background In this study, we compared our experience about early and midterm follow-up outcomes for right anterolateral minithoracotomy (RAMT) vs full sternotomy (FS) in surgical aortic valve replacement (AVR) among adolescents with bicuspid aortic valve (BAV). Methods Patients were retrospectively enrolled from January 2008 to December 2017. Inclusion criteria were patients with BAV who had to undergo to AVR. They were divided in two groups: RAMT and FS. The choice of RAMT was based on individual surgeon's preferences or when expressly requested by patient that was informed of nonconventional approach. Results We enrolled 61 patients, 23 in RAMT group and 38 in FS group. The mean age was 15.6 ± 1.7 years for RAMT group and 16.1 ± 1.5 years for FS group (P = .23). The RAMT group had a higher prevalence of female gender (P = .04). The patients in the RAMT group had longer cardiopulmonary bypass (115.2 ± 18.5 vs 102.2 ± 16.5 min; P = .006) and cross-clamp time (78.6 ± 18.1 vs 74.3 ± 15.2 min; P = .01). No patients required intraoperative conversion to FS. No differences were found in ventilation times, postoperative intensive care unit (ICU), and hospital length of stay for both groups. Follow-up echocardiograms were available for all patients at median of 5.2 years (range 0.5-9.6 years, median 5.4 years for RAMT and 5.1 for FS) and no patient required reoperation for aortic prosthesis malfunction. Conclusions Our study shows that RAMT is safe and effective as FS. Although the RAMT operation takes slightly more operation time, it is not associated with major adverse effects.

Neue technische Entwicklungen auf dem Gebiet der endovaskularen Versorgung infrarenaler Aortenaneurysmen (EVAR) fuhren dazu, dass ein immer groseres Spektrum an unterschiedlichen Aortenpathologien einer minimal-invasiven Therapie zugefuhrt werden kann. Die Verbesserung von Einfuhrkathetern hinsichtlich Diameter und Stabilitat kombiniert mit Flexibilitat sind wichtige Parameter, die insbesondere bei ungunstigen stenosierten iliakalen Zugangswegen entscheidend fur die Machbarkeit einer EVAR werden. Einfachheit und Effektivitat in der Anwendung fuhren zu mehr Sicherheit und Erhohung der Prozedurqualitat beim Interventionalisten zugunsten der Behandlungsqualitat des Patienten. Die Weiterentwicklung der Aortenstentprothesen mit der Moglichkeit zur Repositionierung, aktiver Positionierbarkeit oder neuer Konzepte der endoluminalen Abdichtung lassen eine verbesserte Behandlung einer starken Angulation oder ungunstiger Verankerungszone zu. Dem Interventionalisten kommt eine immer grosere Verantwortung zu, das verfugbare Prothesenmaterial kritisch zu prufen und individuell fur jeden Patienten die am besten geeignete Prothese auszuwahlen. Nur so kann eine sichere Anwendung und ein langfristig optimales Ergebnis gewahrleistet werden.

Transcatheter mitral valve replacement with the Tiara valve can be performed in inoperable patients with severe functional regurgitation. Risk of left ventricular outflow tract obstruction can be prevented using preoperative 3D imaging and 3D-printed models. However, in the case of mono-disk mechanical prostheses previously implanted in aortic position (Bjork-Shiley), there is an additional risk of mechanical interference leading to reduced leaflet motion and aortic valve dysfunction. Hereafter, we describe the case of a patient with a 27-mm mono-disk mechanical aortic valve implanted in 1978, a EuroSCORE II of 18%, and a Society of Thoracic Surgeon score (mortality) of 16% who successfully underwent a transapical Tiara valve implantation.

Background: The impact of prosthesis-patient mismatch (PPM) on early and late outcomes after aortic valve replacement (AVR) remains controversial. In this study, we aimed to investigate the patient and surgery-related factors leading to various severities of PPM following AVR. Methods: Ninety-six patients who had undergone AVR with a prosthetic valve between 2001 and 2013 and later found to have PPM were enrolled. PPM was defined as the indexed effective orifice area (iEOA) of the aortic prosthesis to be ≤0.8 cm2/m2. PPM was considered to be of moderate or severe degrees if the iEOA was between 0.66 and 0.85 cm2/m2 or ≤0.65 cm2/m2, respectively. Results: The mean age of patients was 26 ± 15 years, and 51% of patients were female. Sixteen patients (15.2%) had mild PPM, 40 patients (38.1%) had moderate PPM, and 40 patients (38.1%) had severe PPM. The majority of our patients had surgery due to congenital causes. Prosthetic valve size and preoperative left ventricular outflow tract diameter were factors statistically related to PPM in the three groups (P < 0.05). There was only one death that was in severe PPM group due to severe heart failure. Conclusion: PPM is a substantial yet underrated clinical entity in patients undergoing prosthetic valve replacement surgery. Patients with smaller body surface areas, surgery at earlier age, and underlying congenital heart disease are more commonly prone to the development of PPM. As our center is referral for the patients affected with congenital aortic valve disease, mindful scheduling and performance of the aortic valve replacement surgery in this patient population is highly recommended.

Objective In the present study, we have reported and compared aortoduodenal fistulas (ADFs) after endovascular abdominal aortic aneurysm repair (EVAR) vs after open aortic repair (OAR). Methods We retrospectively analyzed the data from patients treated for ADFs from January 2015 to May 2020 in our hospital. The clinical data, diagnostic procedures, and surgical options were evaluated. The primary endpoints of the present study were 30-day and 1-year mortality. The secondary endpoints were major postoperative complications. Results A total of 24 patients (20 men; median age, 69 years; range, 53-82 years) were admitted with ADFs after EVAR (n = 9) or OAR (n = 15). These patients accounted for ∼4.3% of all abdominal aortic aneurysm repairs in our hospital. The median interval from the initial aortic repair and the diagnosis of ADF was 68 months (range, 6-83 months) for the ADF-EVAR group and 80 months (range, 1-479 months) for the ADF-OAR group. Three patients in the ADF-EVAR group had refused surgical treatment owing to their high surgical risk. One patient in the ADF-OAR group had undergone removal of the aortic prosthesis without replacement. Of the remaining 20 patients, 12 (ADF-EVAR group, n = 4; ADF-OAR group, n = 8) had undergone in situ replacement of the aorta and 8 (ADF-EVAR group, n = 2; ADF-OAR group, n = 6) had undergone extra-anatomic reconstruction with aortic ligation. After a mean follow-up of 26 months, no patient had experienced early limb loss. However, one case of rupture of the venous graft (ADF-EVAR), one case of aortic stump blowout (ADF-OAR), and one case of a ureteroarterial fistula with a homograft (ADF-OAR) had occurred. Overall, the incidence of postoperative complications was significantly greater after ADF-OAR (93% vs 33%; P = .036). The most frequent bacteria involved in the blood cultures were Escherichia coli (25% of patients), and Candida spp. (61%) were the predominant pathogens found on intra-abdominal smears. The in-hospital mortality rates for the ADF-EVAR and ADF-OAR group were 22% and 13%, respectively. The corresponding 1 -year mortality rates were 22% and 33%. Conclusions Patients with ADFs after EVAR or OAR have limited overall survival. In addition to the similar therapeutic approaches, we found no significant differences in postoperative mortality between these two uncommon pathologic entities. In our study, the overall postoperative morbidity seemed greater for the ADF-OAR group.